Novo Nordisk A/S Class B (NOVOb)

Copenhagen
Currency in DKK
569.4
+11.9(+2.13%)
Closed
NOVOb Scorecard
Full Analysis
Has raised its dividend for 7 consecutive years
Fair Value
Day's Range
559.8575.6
52 wk Range
526.01,033.2
Key Statistics
Edit
Prev. Close
569.4
Open
561
Day's Range
559.8-575.6
52 wk Range
526-1,033.2
Volume
2.52M
Average Volume (3m)
4.22M
1-Year Change
-33.08%
Book Value / Share
32.31
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NOVOb Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
813.2
Upside
+42.81%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high P/E ratio relative to near-term earnings growth
Show more

Novo Nordisk A/S Class B Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Employees
76826
Market
Denmark

Compare NOVOb to Peers and Sector

Metrics to compare
NOVOb
Peers
Sector
Relationship
P/E Ratio
25.0x18.6x−0.7x
PEG Ratio
1.160.010.00
Price/Book
17.6x3.1x2.6x
Price / LTM Sales
8.7x2.8x3.1x
Upside (Analyst Target)
34.4%15.6%47.6%
Fair Value Upside
Unlock15.9%7.7%Unlock

Analyst Ratings

16 Buy
6 Hold
2 Sell
Ratings:
24 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 813.2
(+42.81% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 22.67
Dividend Yield
2.00%
Industry Median 1.56%
Annualised payout
11.4000
Paid unevenly
5-Years Growth
+22.25%
Growth Streak

Earnings

Latest Release
-
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

People Also Watch

343.00
OREP
-0.10%
104.04
SASY
+0.33%
2,809.00
HRMS
-1.06%
82.42
NESN
-0.07%
6.370
QBTS
-2.00%

FAQ

What Is the Novo Nordisk B (NOVOb) Stock Price Today?

The Novo Nordisk B stock price today is 569.40

What Stock Exchange Does Novo Nordisk B Trade On?

Novo Nordisk B is listed and trades on the Copenhagen stock exchange.

What Is the Stock Symbol for Novo Nordisk B?

The stock symbol for Novo Nordisk B is "NOVOb."

Does Novo Nordisk B Pay Dividends? What’s The Current Dividend Yield?

The Novo Nordisk B dividend yield is 2.04%.

What Is the Novo Nordisk B Market Cap?

As of today, Novo Nordisk B market cap is 2.53T.

What is Novo Nordisk B Earnings Per Share?

The Novo Nordisk B EPS is 22.67.

What Is the Next Novo Nordisk B Earnings Date?

Novo Nordisk B will release its next earnings report on 06 May 2025.

From a Technical Analysis Perspective, Is NOVOb a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.